LATHAM, N.Y., February 15, 2024–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that […]
Tag: AngioDynamics
AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the United States Food […]
AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2024, which ended November 30, 2023. “Today, we are announcing meaningful steps in our strategic transformation. We have initiated a restructuring of our
AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for […]
AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of […]
Merit Medical Announces Acquisition of Dialysis Catheter Portfolio and the BioSentry® Biopsy Tract Sealant System from AngioDynamics, Inc. and Acquisition of the Surfacer® Inside-Out® Access Catheter System from Bluegrass Vascular Technologies, Inc.
Acquisitions broaden Merit’s therapeutic platform with diverse dialysis product solutions and expand its access catheter offering Acquisitions projected to add approximately $30 million of revenue, on an annualized basis, in key strategic markets that leverage existing commercial footprint Merit re-affirms […]
AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance
Fiscal Year 2023 Third Quarter Highlights Net sales of $80.7 million increased 9.1% compared to the prior-year quarter Med Tech net sales of $22.9 million increased 16.6% Med Device net sales of $57.8 million increased 6.4% Gross margin of 50.2% […]
AngioDynamics Reports Fiscal 2023 Second Quarter Financial Results; Reaffirms Guidance
Fiscal Year 2023 Second Quarter Highlights Net sales of $85.4 million increased 9.1% compared to the prior-year quarter Med Tech net sales of $24.5 million increased 29.7% Med Device net sales of $60.9 million increased 2.6% Gross margin of 52.8% […]
AngioDynamics Reports Fiscal 2023 First Quarter Financial Results; Reaffirms Guidance
Fiscal Year 2023 First Quarter Highlights Net sales of $81.5 million increased 5.9% compared to the prior-year quarter Med Tech net sales of $22.8 million increased 29.6% Med Device net sales of $58.7 million decreased 1.1% Gross margin of 51.9% […]
AngioDynamics Reports Fiscal Year 2022 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2023 Guidance
Fiscal Year 2022 Fourth Quarter Highlights Net sales of $87.0 million increased 13.2% compared to the prior-year quarter Gross margin of 53.4% declined 170 basis points year over year GAAP loss per share of $0.16 and adjusted earnings per share […]